×

Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid(R) in people with type 1 and type 2 diabetes

BAGSVAERD, Denmark, March 25, 2015 (GLOBE NEWSWIRE) -- Novo Nordisk today announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset® 1 and onset® 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid® (insulin aspart) in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively.

For further information

Media:
Mike Rulis +45 3079 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company Announcement No 22 2015

Company Announcement No 22 2015 http://hugin.info/2013/R/1906174/678581.pdf

HUG#1906174

Source:Novo Nordisk A/S